Matthijs van der Meulen1, Linda Dirven2,3, Katerina Bakunina4, Martin J van den Bent5, Samar Issa6, Jeanette K Doorduijn7, Jacoline E C Bromberg5. 1. Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, Netherlands. m.vandermeulen.2@erasmusmc.nl. 2. Department of Neurology, Leiden University Medical Center, Leiden, Netherlands. 3. Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands. 4. Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 5. Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, Netherlands. 6. Department of Hematology, Middlemore Hospital, Auckland, New Zealand. 7. Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
Abstract
INTRODUCTION: To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. METHODS: In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed PCNSL were randomized between high-dose methotrexate-based chemotherapy with or without rituximab. Data on potential (MMSE-score), and known baseline prognostic factors (age, performance status, serum LDH, cerebrospinal fluid total protein, involvement of deep brain structures, multiple cerebral lesions, and the IELSG-score) were collected prospectively. Multivariable stepwise Cox regression analyses were used to assess the prognostic value of all factors on progression-free survival (PFS) and overall survival (OS) among patients with available MMSE score at baseline. Age was analyzed as continuous variable, the MMSE-score both as a continuous and as a categorical variable. RESULTS: In univariable analysis, age, MMSE-score and whether the patient received rituximab were statistically significantly prognostic factors for PFS. Age and MMSE-score were statistically significantly associated with OS. In a multivariable analysis of the univariately significant factors only MMSE-score was independently associated with the survival endpoints, as a continuous variable (HR for PFS 1.04, 95% CI 1.01-1.08; OS 1.06 (95% CI 1.02-1.10) and as categorical variable HR (< 27 versus ≥ 27 for PFS 1.55 (1.02-2.35); OS 1.68 (1.05-2.70). In our population, performance status, serum LDH, and CSF protein level were not of prognostic value. CONCLUSION: Neurocognitive disturbances, measured with the MMSE at baseline, are an unfavorable prognostic factor for both PFS and OS in adult PCNSL patients up to 70 years-old.
INTRODUCTION: To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. METHODS: In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed PCNSL were randomized between high-dose methotrexate-based chemotherapy with or without rituximab. Data on potential (MMSE-score), and known baseline prognostic factors (age, performance status, serum LDH, cerebrospinal fluid total protein, involvement of deep brain structures, multiple cerebral lesions, and the IELSG-score) were collected prospectively. Multivariable stepwise Cox regression analyses were used to assess the prognostic value of all factors on progression-free survival (PFS) and overall survival (OS) among patients with available MMSE score at baseline. Age was analyzed as continuous variable, the MMSE-score both as a continuous and as a categorical variable. RESULTS: In univariable analysis, age, MMSE-score and whether the patient received rituximab were statistically significantly prognostic factors for PFS. Age and MMSE-score were statistically significantly associated with OS. In a multivariable analysis of the univariately significant factors only MMSE-score was independently associated with the survival endpoints, as a continuous variable (HR for PFS 1.04, 95% CI 1.01-1.08; OS 1.06 (95% CI 1.02-1.10) and as categorical variable HR (< 27 versus ≥ 27 for PFS 1.55 (1.02-2.35); OS 1.68 (1.05-2.70). In our population, performance status, serum LDH, and CSF protein level were not of prognostic value. CONCLUSION: Neurocognitive disturbances, measured with the MMSE at baseline, are an unfavorable prognostic factor for both PFS and OS in adult PCNSL patients up to 70 years-old.
Entities:
Keywords:
MMSE; Primary central nervous system lymphoma; Prognosis
Authors: Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Jacoline E C Bromberg; Samar Issa; Katerina Bakunina; Monique C Minnema; Tatjana Seute; Marc Durian; Gavin Cull; Harry C Schouten; Wendy B C Stevens; Josee M Zijlstra; Joke W Baars; Marcel Nijland; Kylie D Mason; Aart Beeker; Martin J van den Bent; Max Beijert; Michael Gonzales; Daphne de Jong; Jeanette K Doorduijn Journal: Lancet Oncol Date: 2019-01-07 Impact factor: 41.316
Authors: Thomas B Daniels; Paul D Brown; Sara J Felten; Wenting Wu; Jan C Buckner; Robert M Arusell; Walter J Curran; Ross A Abrams; David Schiff; Edward G Shaw Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-05 Impact factor: 7.038
Authors: Paul D Brown; Jan C Buckner; Judith R O'Fallon; Nancy L Iturria; Cerise A Brown; Brian P O'Neill; Bernd W Scheithauer; Robert P Dinapoli; Robert M Arusell; Walter J Curran; Ross Abrams; Edward G Shaw Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544